SCHEMBL4878872

SCHEMBL4878872

COc1cccc(Cn2c(-c3ccc4nc(-c5ccc(F)cc5)ccc4c3)c(C3CCCCC3)c3sc(C(=O)O)cc32)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.37
CYP1A2 P05177 3/20 0.37
CYP3A4 P08684 3/20 0.37
ALDH1A1 P00352 3/20 0.37
CYP2C9 P11712 2/20 0.37
CYP2C19 P33261 2/20 0.37
USP2 O75604 1/20 0.37
CYP2D6 P10635 1/20 0.37
ALOX15 P16050 1/20 0.37
MAPK1 P28482 1/20 0.37
KDM4E B2RXH2 1/20 0.36
HPGD P15428 1/20 0.36
KIT P10721 2/20 0.36
GRIN1 Q05586 1/20 0.35
GRIN2B Q13224 1/20 0.35
CASP1 P29466 1/20 0.35
CASP7 P55210 1/20 0.35
HSD17B10 Q99714 1/20 0.35
MEN1 O00255 1/20 0.35
TSHR P16473 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4871781 0.94 MAPT (0.37) HSD17B10MEN1KMT2ATHRBALOX5AP
SCHEMBL4871839 0.93 ALOX5AP (0.40) LMNAALOX5AP
SCHEMBL4867728 0.90 ALOX5AP (0.41) ALDH1A1THRBALOX5APMAPT
SCHEMBL4878213 0.89 KCNH2 (0.37) HSD17B10MEN1KMT2ATHRBMAPT
SCHEMBL4868482 0.89 PPARG (0.38) LMNAMAPT
SCHEMBL4868806 0.88 KCNH2 (0.36) LMNAHSD17B10MEN1KMT2ATHRB
SCHEMBL4876393 0.87 ALOX5AP (0.34) LMNAHSD17B10MEN1KMT2ATHRB
SCHEMBL4868454 0.87 CCR2 (0.38) LMNACYP1A2CYP3A4ALDH1A1CYP2C9
SCHEMBL4879012 0.87 ALOX5AP (0.35) CYP2D6ALOX5APMAPT
SCHEMBL4878878 0.87 LMNA (0.40) LMNACYP1A2CYP3A4ALDH1A1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080051384-A1 ANTIVIRAL AGENTS GENELABS TECHNOLOGIES, INC. 2008-02-28 US disclosed
US-20080051384-A1 ANTIVIRAL AGENTS GENELABS TECHNOLOGIES, INC. 2008-02-28 US disclosed
US-20080051384-A1 ANTIVIRAL AGENTS GENELABS TECHNOLOGIES, INC. 2008-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080051384-A1 ANTIVIRAL AGENTS EIF2AK2, MAVS, ZC3HAV1 LMNA 3337/4885CYP1A2 1715/4885CYP3A4 1081/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.